272 related articles for article (PubMed ID: 26585599)
1. Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.
Bus P; Kestens C; Ten Kate FJ; Peters W; Drenth JP; Roodhart JM; Siersema PD; van Baal JW
J Gastroenterol; 2016 Jun; 51(6):560-70. PubMed ID: 26585599
[TBL] [Abstract][Full Text] [Related]
2. Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma.
Chiam K; Wang T; Watson DI; Mayne GC; Irvine TS; Bright T; Smith L; White IA; Bowen JM; Keefe D; Thompson SK; Jones ME; Hussey DJ
J Gastrointest Surg; 2015 Jul; 19(7):1208-15. PubMed ID: 25943911
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis.
Fassan M; Realdon S; Cascione L; Hahne JC; Munari G; Guzzardo V; Arcidiacono D; Lampis A; Brignola S; Dal Santo L; Agostini M; Bracon C; Maddalo G; Scarpa M; Farinati F; Zaninotto G; Valeri N; Rugge M
Pathol Res Pract; 2020 May; 216(5):152907. PubMed ID: 32131978
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.
Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ
World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310
[TBL] [Abstract][Full Text] [Related]
6. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
[TBL] [Abstract][Full Text] [Related]
7. Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus.
Chiam K; Mayne GC; Wang T; Watson DI; Irvine TS; Bright T; Smith LT; Ball IA; Bowen JM; Keefe DM; Thompson SK; Hussey DJ
World J Gastroenterol; 2020 May; 26(20):2570-2583. PubMed ID: 32523312
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer.
Garman KS; Owzar K; Hauser ER; Westfall K; Anderson BR; Souza RF; Diehl AM; Provenzale D; Shaheen NJ
Dig Dis Sci; 2013 Nov; 58(11):3178-88. PubMed ID: 23925817
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study.
Revilla-Nuin B; Parrilla P; Lozano JJ; de Haro LF; Ortiz A; Martínez C; Munitiz V; de Angulo DR; Bermejo J; Molina J; Cayuela ML; Yélamos J
Ann Surg; 2013 May; 257(5):886-93. PubMed ID: 23059500
[TBL] [Abstract][Full Text] [Related]
11. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.
Dong J; Buas MF; Gharahkhani P; Kendall BJ; Onstad L; Zhao S; Anderson LA; Wu AH; Ye W; Bird NC; Bernstein L; Chow WH; Gammon MD; Liu G; Caldas C; Pharoah PD; Risch HA; Iyer PG; Reid BJ; Hardie LJ; Lagergren J; Shaheen NJ; Corley DA; Fitzgerald RC; ; Whiteman DC; Vaughan TL; Thrift AP
Gastroenterology; 2018 Apr; 154(5):1273-1281.e3. PubMed ID: 29247777
[TBL] [Abstract][Full Text] [Related]
12. Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.
Shah AK; Cao KA; Choi E; Chen D; Gautier B; Nancarrow D; Whiteman DC; Saunders NA; Barbour AP; Joshi V; Hill MM
Mol Cell Proteomics; 2015 Nov; 14(11):3023-39. PubMed ID: 26404905
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
Mallick R; Patnaik SK; Wani S; Bansal A
Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
[TBL] [Abstract][Full Text] [Related]
14. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Expression can be a Promising Strategy for the Detection of Barrett's Esophagus: A Pilot Study.
Bansal A; Hong X; Lee IH; Krishnadath KK; Mathur SC; Gunewardena S; Rastogi A; Sharma P; Christenson LK
Clin Transl Gastroenterol; 2014 Dec; 5(12):e65. PubMed ID: 25502391
[TBL] [Abstract][Full Text] [Related]
16. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus.
Bansal A; Gupta V; Wang K
J Cell Biochem; 2016 Jun; 117(6):1288-95. PubMed ID: 26808728
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
Campos VJ; Mazzini GS; Juchem JF; Gurski RR
J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
[TBL] [Abstract][Full Text] [Related]
19. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Zhang T; Wang Q; Ma WY; Wang K; Chang X; Johnson ML; Bai R; Bode AM; Foster NR; Falk GW; Limburg PJ; Iyer PG; Dong Z
EBioMedicine; 2019 Nov; 49():145-156. PubMed ID: 31707149
[TBL] [Abstract][Full Text] [Related]
20. A review of the current understanding and clinical utility of miRNAs in esophageal cancer.
Sakai NS; Samia-Aly E; Barbera M; Fitzgerald RC
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):512-21. PubMed ID: 24013023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
